News

Treatment failure occurred in 10% of the intensive treatment group compared to 28% in the standard treatment group

TAK-755, a recombinant ADAMTS13, is examined for its therapeutic benefit to patients with sickle cell disease and patients with cTTP.

Prominent dermatologists detail how a biased literature, a lack of education, accessibility issues, and historical wrongdoings have all influenced the study of skin of color.

Investigators believe this could be a good option for patients who did not respond to a first-line biologic, though further research is required.

The treatment resulted in a significant reduction of proteinuria from baseline in 34% of trial participants.

Investigators added that clinical condition at the time of vaccination and biologic treatment did not influence the humoral response in the enrolled patients.

Data show a total absence of influenza-related hospitalization and mortality during the 2020 - 2021 influenza season in Canada.

Stigma, and a lack of communication and awareness all inhibit HIV PrEP uptake, but digital health and new forms of PrEP could boost users.

The approval represents the first ever treatment for the disease in patients aged 2 years and older.

Eli Lilly and Company is expected to apply for a Biologics License Application in the first half of 2022.

Data show the weighted influenza vaccination rate among pregnant women was 54.5%, with one third not having a usual source of care.

Investigators suggest that improvements to care could be made based on experiences and recommendations from patients with chronic hand eczema.

The enrollment distribution was consistent by ethnicity over the course of 18 years, with no change in diversity over time despite there being an increase in the UK in the minority population.

Half of all cases of vitiligo occur in childhood, and accessibility to therapy has been an ongoing issue.

Of the SCD patients who contracted COVID-19, 49% of them visited the Grady Comprehensive Sickle Cell center because of a vaso-occlusive event.

Data show patients with sickle cell disease identified by distinct cognitive profile should have neurorehabilitation tailored to each unique profile.

Biologics account for significant healthcare-related costs for patients with either ulcerative colitis or Crohn’s disease.

After 2 months of voxelotor treatment, all patients with sickle cell anemia perceived global improvement, but peak VO2 did not change in 8 of 9 patients.

Data show most patients (60.3%) with sickle cell disease achieved a Hb increase of >1 g/dL during the follow-up period.

Patients with SCD were not at an increased risk of death or disease complications.

High dose vitamin D supplementation has been linked to fewer pain days and higher physical activity scores for patients with chronic pain.

New ASH 2021 data for the stem cell transplant therapy suggest it has a durable and safe benefit for adults with severe disease.

Investigators added improvements were needed regarding access to complete diagnostic evaluation among Black patients, citing disparities in care.

Data show the majority of patients who initiated crizanlizumab remained on therapy, while a third of patients saw barriers including insurance coverage.

New research on the preclinical product TALGlobin01 reveals the potential impact that gene therapy can have on the future of sickle cell disease treatment.

New cohort analysis suggest a heightened risk of atrial fibrillation may be worsening patients' life expectancies.

Investigators aimed to improve lentiviral vectors to boost therapeutic β-like globin levels without increasing the mutagenic vector load in hematopoietic stem/progenitor cells.

Data from the ADQoC Initiative show that patients with AD are often misdiagnosed or the severity of their disease was undertreated.